Rosiglitazone maleate for moderate to severe plaque psoriasis - horizon scanning review
National Horizon Scanning Centre
Record ID 32005000231
English
Authors' objectives:
This study aims to assess the effectiveness of rosiglitazone maleate for moderate to severe plaque psoriasis.
Authors' recommendations:
Rosiglitazone maleate (Avandia), a thiazolidindione is currently in phase III clinical trials for the treatment of moderate to severe chronic plaque psoriasis. It is a selective and potent agonist of the peroxisome proliferators-activated receptor- (PPAR-), which inhibits cytokine production and promotes cell differentiation. It is administered orally at a dose of between 2mg and 8mg. There are no published clinical trials available at this time.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
http://www.pcpoh.bham.ac.uk/publichealth/horizon/
Year Published:
2005
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Dermatologic Agents
- Psoriasis
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.